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Nitric oxide (NO) is a diatomic gaseous molecule generated in our bodies by enzymes 
known as NO synthases. More recently another pathway for generation of NO has been 
delineated in which dietary or endogenous inorganic nitrate and nitrite are metabolized 
to form NO. Dietary supplementation with nitrate has proven beneficial for a number of 
disorders e.g. by improving metabolic function and lowering blood pressure, making it 
an attractive novel drug candidate in metabolic and cardiovascular disease. Besides 
utilizing direct therapeutic effects of nitrate itself, another attractive option might be to 
combine nitrate with another drug in order to increase the overall effect or reduce the 
side effects of the other drug.   
 
The aim of the proposed thesis was to determine whether simultaneous acute 
administration of a low dose of metformin and nitrate can act synergistically to improve 
metabolic functions and decrease blood glucose level in a metabolic syndrome genetic 
mouse model (A2BKO mice) and also if this combination can prevent lactic acidosis 
produced by metformin in rats. 
 
The results showed that both nitrate and metformin alone had a beneficial effect on 
glucose tolerance but there was no clear synergistic effect to decrease blood glucose 
levels. We speculate that the lack of synergy may be due to their same mechanism of 
action in targeting NADPH oxidase and AMP-activated protein kinase. However, the 
glucose disposal was better in metformin and nitrate combination group compared to 
metformin group. Moreover, in separate experiments we found that acute administration 
of nitrate had no impact on prevention of lactic acidosis induced by high dose of 
metformin in rats. However, future chronic studies are necessary in order to ameliorate 
our knowledge of the proposed combination mechanism. 
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The metabolic syndrome has become a serious public challenge in recent years. It was 
first delineated in 1923 by Kylin as a triad of hypertension (high blood pressure), 
hyperglycaemia (high blood glucose) and hyperuricaemia (high blood uric acid) [1].  
In 1947 Vague revealed that distribution of body fat has a great impact on the 
development of metabolic disease [2] and in 1988 Reaven revealed that the so called 
syndrome X contributes to insulin resistance, excess amount of insulin and glucose in 
blood, decreased HDL cholesterol, high level of VLDL triglycerides and hypertension 
[3]. The metabolic syndrome contributes to type 2 diabetes (T2D) and cardiovascular 
disease. The risk factors of metabolic disease are as follows, abdominal obesity, 
elevated blood pressure and high level of fasting plasma glucose, low amount of high-
density lipoprotein (HDL) and high serum triglycerides [4].  
Based on the IDF definition, in order to be recognized with metabolic disease, 
individuals should have abdominal girth more than or equal to 94cm for men and more 
than or equal to 80cm for women, in addition to any two following risk factors: high 
blood pressure (diastolic blood pressure more than or equal to 85 mmHg or a systolic 
blood pressure more than or equal to 130 mmHg, or treatment of previously diagnosed 
hypertension; increased fasting plasma glucose (more than or equal to 100 mg/dL or 
have type 2 diabetes); high level of triglycerides (more than or equal to 150 mg/dL or 
treatment of previously diagnosed lipid abnormality); and reduced HDL cholesterol (for 
men: less than 40 mg/dL and for women:less than 50 mg/dL or specific treatment for 
this lipid abnormality) (http://www.idf.org). Moreover, insulin resistance in which body 
cells do not respond normally to insulin, obesity and inferior physical activity may 
contribute to development of metabolic syndrome. The metabolic syndrome increases 







1.1. Weight Gain and the Relationship to the Metabolic Syndrome 
 
Obesity is recognized as a global epidemic [7] and is closely linked with an increased 
risk for the metabolic disease. Elevated amounts of fat in the body, particularly in the 
liver may result in insulin resistance and atherogenic dyslipidemia which may lead to 
high level of triglycerides and low level of HDL cholesterol in blood [8]. Most of the 
individuals diagnosed with metabolic disorder are obese (BMI of 30 kg/m2 or above) or 
overweight (BMI of 25 kg/m2 to 29.9 kg/m2 ) [9, 10]. The metabolic disorder was 
diagnosed in 4.6% of normal weight men, 59.6% of obese men and 22.4% of 
overweight men and also in 6.2% of normal weight women, 28.1% of overweight 
women and 50.0% of obese women [10]. Middle-aged men who gained weight since 20 
years of their age are at higher risk of developing metabolic disease [11]. Moreover, 
weight gain during adulthood in women, is associated with higher risk of cardiovascular 
problems [12] and in general, individuals with weight gain during the last 10 to 15 years 
of their current age are more likely to develop metabolic disease in comparison with 
those with stable body weight [13].  
 
1.2. Metabolic Syndrome and physical activity 
 
Physical activity is body’s movement which in consequence causes energy 
disbursement [14]. According to various studies, physical activity is closely linked with 
less risk of developing metabolic disease [15-19] and individuals with inferior physical 
activity can be at risk of developing metabolic disorder. 
Frequent physical activity has a great positive impact on metabolic syndrome. It 
decreases body weight and fat accumulation, blood pressure and triglyceride levels. It 
also increases HDL cholesterol and improves sensitivity of insulin [18, 20, 21]. Rennie 
and colleagues [15] revealed that increasing physical activity contributes to decreased 
risk of developing metabolic syndrome in individuals independent of age, heavy alcohol 





Nitrate is a major component of our daily diet and is mostly found in green leafy 
vegetables. Moreover, nitrite and nitrate are used as preserving agents for meat products 
such as sausages, hot dogs and bacon. The proper daily intake amount of nitrate 
announced by the World Health Organisation is 0–3.7 mg/kg. Nitrate concentration in 
various food types is shown in Table 1 [22]. Nitrate was commonly believed as a 
harmful compound for our health until recent years. Based on the report from 
International Agency for Research on Cancer (IARC) in 2010, inorganic nitrate can 
trigger carcinogenesis. However, as described in more detail below it turns out to have 
various unexpected beneficial protective effects in animal models and in human. These 
include prevention from ischaemia reperfusion injury, lowering blood pressure, 
improved metabolic function and protection against gastric ulceration. According to 
recent epidemiological studies green leafy vegetables have shown to be protective 
against metabolic disease, cardiovascular problems and obesity [23, 24]. Moreover, it 
has been discussed recently that there is likely no link between inorganic nitrate 
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1.3.1. The nitrate-nitrite-NO pathway 
 
There are two different pathways for NO formation in the body, the NOS-dependent 
pathway in which nitric oxide synthase (NOS) generates NO from L-arginine in the 
presence of oxygen molecule and the more recently discovered nitrate-nitrite-NO 
pathway that can be a replaced pathway for nitric oxide production particularly under 
oxidative stress and during tissue hypoxia [29]. 
In the classic pathway, NO is generated from L-arginine amino acid and NOS (nitric 
oxide synthases) in the presence of oxygen. NOS has three isoforms, calcium-dependent 
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forms which consist of endothelial nitric oxide synthases (eNOS) and neuronal nitric 
oxide synthases (nNOS) which generate small amounts of nitric oxide in response to 
elevated amounts of intracellular Ca2+ and a Ca2+-independent nitric oxide synthase 
(iNOS or inducible NOS) form which is involved in immune responses and mostly 
localized in macrophages and neutrophils. 
In 1994, Benjamin and Lundberg who were working independently found that great 
amounts of nitric oxide are produced intragastrically in humans [30, 31]. This NO was 
found to be generated non-enzymatically by the acid dependent reduction of inorganic 
nitrite. It was discovered that inorganic nitrate is the substrate for this NO. Nitrate is 
concentrated and accumulated in saliva and then it is converted to reactive nitrite by 
commensal bacteria residing in oral cavity [32, 33]. Then nitrite forms NO in the 
stomach. Some nitrite also escapes the stomach and is absorbed into bloodstream. In 
blood and tissues there are various pathways to reduce nitrite further to form NO. These 
include xanthine oxidoreductase (XOR), deoxymyoglobin, deoxyhemoglobin, 
mitochondrial respiratory chain enzymes and a low tissue pH [34]. The NO formed 
causes vasodilation and regulates blood pressure in the body and also improves 







Figure 1. Comparison of two different pathways for nitric oxide formation in mammals. 
Image from reference [24]. 
 
 
1.3.2. Nitric Oxide, Mitochondria and the Relationship to the Metabolic  
Syndrome 
 
In the nitrate-nitrite-NO pathway, inorganic nitrate, which can be provided either from 
the diet or NO oxidation in the body, is reduced to reactive nitrite through commensal 
bacteria residing in the mouth and to a lesser extent through XOR. Reduced NO 
bioavailability in the body and increased oxidative stress occur during aging and also 
lead to development of metabolic disorders, and hypertension.  
Mitochondria are crucial players in energy metabolism and therefore any alteration or 
defect in their function can result in metabolic disorders [38]. Studies have shown that 
NO improves mitochondrial function and respiration [39]. Moreover, decreased NO 
generation from eNOS is claimed to be a crucial event in metabolic disorders [40]. NO 
is a cellular signaling molecule, it regulates a lot of physiological processes in our body 
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e.g by preventing aggregation of platelets and neutrophils attachment to the vessels’ 
endothelium. It also has cytotoxic and cytostatic features which is of importance in 
immune regulation and host defence. Other features of NO is that it directly affects 
mitochondrial respiration [41] and regulates the tone of vascular smooth muscle. 
Studies have revealed that defects in NOS activity or overall NO bioavailability will 
result in insulin resistance [42]. Shankar and colleagues demonstrated such relationship 
between insulin sensitivity and nitric oxide in eNOS knockout mice [43]. Another study 
in 2007, on healthy newborns’ umbilical vein endothelial cells with a genetic family 
background of type 2 diabetes revealed that these newborns have abnormal intracellular 
NO synthesis and defects in p53, GLUT1 and eNOS gene expression [44]. 
In recent years, scientists have studied different ways of regulating NO signaling 
pathways, including manipulations of the nitrate-nitrite-NO pathway (eg. with dietary 
interventions) [23, 24, 45]. It has been proven that supplementation of dietary nitrate 
can reverse some markers of metabolic disease which exist in eNOS impaired mice 
[46]. Recently a study showed that chronic inorganic nitrite administration in a model of 
obesity, through higher rates of AMP activated kinase (AMPK) phosphorylation, 
ameliorated some components of metabolic disorder [47]. Moreover, oxidative stress 
and hypertension in animal models of cardiovascular and renal disease can be decreased 
by chronic nitrite treatment [48, 49].  
 
1.3.3. Nitrate and adipose tissue metabolism 
 
Adipose tissue has a significant role in energy homoeostasis. Obesity occurs due to 
increased adipocyte size and accretion of white adipose tissue (WAT). WAT is a source 
of energy in the body which can be released through lipolysis [50]. Another component 
of the adipose organ is brown adipose tissue (BAT) that transfers energy from food into 
heat during the non-shivering thermogenesis process [51]. Thermogenesis might have 
anti-obesity properties since it contributes to higher rates of fatty acid catabolism and 
lipolysis [52]. In general, BAT has larger number of mitochondria in comparison with 
WAT and recently it has been discovered that dietary nitrate can transform certain 
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depots of WAT into BAT with increases in mitochondrial function and fatty acid 
oxidation in hypoxic WAT [53]. One important function of dietary nitrate in adipose 
tissue is likely to increase cGMP concentrations [54, 55] which in turn regulates energy 
metabolism through activation of differentiation of adipocyte and lipolysis [56-58]. 
Indeed, in 2013, cGMP was identified as a molecule that stimulates the browning 
response in WAT [59]. Later, it was concluded that nitrate triggers the browning 
response in adipose tissue by cGMP signaling and nitrate-nitrite-NO pathway. A study 
in 2010 highlighted that dietary inorganic nitrate can reduce body weight and 






Figure 2. Impact of nitrate on WAT. Nitrate activates browning response 
in WAT through cGMP-PKG pathway and elevated expression of PGC-





1.3.4. Nitrate and hypertension 
 
Dietary inorganic nitrate can attenuate hypertension which is a major feature of 
metabolic disorder and CVD [61]. Hypertension elevates the risk for cardiovascular 
disease several fold depending on severity [62] and according to National Diabetes 
Statistics Report in 2014, 71% of diabetic patients have hypertension. Decreased 
amounts of NO is closely linked with endothelial function impairment and consequently 
hypertension and CVD [63-65]. Therefore, consumption of dietary inorganic nitrate is 
emerging as a potential new strategy to decrease endothelial dysfunction, hypertension, 
CVD and metabolic syndrome by providing NO from nitrate-nitrite-NO pathway [66]. 
A study in 2006 demonstrated that dietary nitrate supplementation for 3 days decreases 
blood pressure both diastolic and systolic [67]. Another study conducted in 2011 
showed that dietary inorganic nitrate improves high blood pressure in patients with 
peripheral artery disease [68]. Finally, a recent study investigated the effect of chronic 
treatment of nitrate-containing beetroot juice during a 4-week period in hypertensives 
and found that it sustainably reduced blood pressure and improved endothelial function 
[69]. 
The kidneys regulate blood pressure through secretion of vasoconstrictors (angiotensin 
II) and vasodilators (NO) [70]. Another potential way for dietary nitrate to exert its 
beneficial effects in hypertension is to specifically target the renal microcirculation [49]. 
According to a recent study, inorganic nitrate also inhibits the production of 
erythropoietin and consequently decreases haematocrit and blood pressure [71]. Indeed, 
a pre-hypertensive state and hypertension is contribute to increased haematocrit [72, 
73]. 
 
1.3.5. Dietary nitrate and the heart 
 
During hypoxia the activity of numerous mitochondrial enzymes may decrease in the 
heart [74, 75]. It has been speculated that dietary nitrate intake may contribute to 
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improvement in mitochondrial function, respiration rate and consequently can protect 
the heart against hypoxia related damage [76]. Moreover, nitrate may increase the 
concentration of L-arginine in the heart by decreasing expression of the enzyme 
arginase which thereby would enhance the production of NO from NO synthases. 
Increased arginase activity contributes to mitochondrial dysfunction and cardiac 
pathologies mainly due to the fact that the enzyme steals substrate (L-arginine) from 
NO synthases, resulting in a decreased NO bioavailability [77-80]. Hence, it is believed 
that dietary inorganic nitrate might be used as a therapeutic agent in heart failure [81, 
82]. 
 
1.4. Adenosine receptors 
 
It has been more than 40 years since adenosine receptors (a type of G protein-coupled 
receptors) were discovered. There are four types of adenosine receptors with different 
functions; 
The A1 receptor is widely expressed in all the body specially, in the brain and 
excitatory nerve endings 24 and exert their effects in various organs and cells. A1 
receptors regulate neuronal activity through blockage of neurotransmitter release. 
 
The A2A receptor is present in immune cells, leukocytes, blood platelets, heart, lung 
and blood vessels thymus and in the brain [83, 84]. Activation of A2A receptor, alters 
the cyclic AMP–protein kinase A (PKA) pathway. Moreover, A2A receptors regulate 
inflammation, myocardial blood flow and oxygen consumption, dopamine and 
glutamate release in the brain and the control of cancer pathogenesis. 
The A2B receptor stimulates AMPK activity and is less sensitive to adenosine 
compared to other adenosine receptors. Therefore, they exert their effect during 




The A3 receptors contribute in many physiological functions and intracellular 
signaling pathways. A3 receptors signaling have anti-inflammatory, anticancer and 
cytoprotective effects. 
 
1.4.1. The A2B adenosine receptor and the metabolic syndrome 
 
Adenosine receptor has been an interesting target in drug discovery and development 
field since 1940s since it has an important role in many diseases. 
The A2b adenosine receptor controls glucose homeostasis [85] in the body and has 
protective effects against impaired glucose metabolism.  It also enhances bone cell 
differentiation [86, 87] and regulates hyperlipidaemia and atherosclerosis. A study in 
2014 showed that the A2b adenosine receptor deletion affected glucose and lipid 
metabolism in mice [88]. A2BR are expressed in most immune cells and regulate 
macrophage activation. Therefore, it seems the insulin resistance can be increased by 
their signal elevation in diabetes due to increase in production of pro-inflammatory 
mediators. A2BR antagonists may be beneficial to treat insulin resistance in diabetes. 
 
1.4.2. A2B-knockout mice  
 
One of the major metabolic organs in the body is the liver, which is the principle site of 
glycogenolysis, glyconeogenesis, gluconeogenesis, lipolysis and lipogenesis [89]. A 
study in 2002 showed that abnormal liver function is a marker of risk for T2DM, and 
insulin resistance [90]. 
The A2BKO mouse model is one of the best metabolic disease animal models and it 
was made by targeted deletion of the A2B receptor gene from the mouse genome which 
leads to abnormalities in the liver, development of metabolic disease and type 2 diabetes 
symptoms. A2BKO mice are characterized by high NOX activity and low AMPK 
phosphorylation in their liver [40]. It has been proved that activation of NOX activity is 
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closely linked with AMPK inhibition in colon cancer cells [91] and elevated NADPH 
oxidase activity in liver can reduce glucose uptake and leads to hyperglycemia [92]. 
Some quiet recent experiments revealed that, A2BKO mice on HFD have impaired 
insulin signaling with abnormal, inflamed and steatotic livers [93, 94]. Another study in 
2014 showed, A2BKO mice which had been fed with normal diet had higher levels of 
triglyceride biosynthesis and liver gluconeogenesis [88] and finally, a study which was 
performed in our research group represented A2BKO mice are a great model of 
metabolic disease and dietary nitrate can reduce blood glucose level [40]. It is still 
unknown why A2BKO mice develop such symptoms but one of the potential hypothesis 
is that A2 receptors are linked to the NOS dependent generation of NO in different 
organs and cells [48, 95]. This type of mice also showed inflammation of the vascular 
system [96] and they usually suffer from vascular leakiness [97]. It is surprising that 
A2BKO mice have strong phenotype [96], although A2B receptors have low affinity for 
adenosine [98]. 
In general, it seems that A2BKO mice constitute a novel model of metabolic disease 
and is suitable model for testing the effect of inorganic nitrate or nitrite on metabolic 
syndrome. 
 
1.5. AMPK as a metabolic regulator 
 
One of the important metabolic regulators which has a great impact on liver glucose 
homeostasis is Adenosine monophosphate kinase (AMPK) [99, 100] which is recently 
suggested to be a novel target of the nitrate-nitrite-NO pathway [47, 101, 102]. 
Typically, under hyperglycemic conditions AMPK activation is decreased. Moreover, 
metformin and AICAR, which are two well-known anti-diabetic drugs, provoke AMPK 






Figure 3. Post-translational modifications triggered by AMPK on PKC can reduce 




Diabetes mellitus is a cluster of diseases associated with high blood glucose 
concentration that is due to the body's dysfunction to produce and/or respond to insulin. 
This situation is defined by the hyper-glycaemia level that can increase the risk of 
retinopathy, nephropathy and neuropathy. According to the WHO classification, two 
types of diabetes are exist, type 1 and type 2. Diabetes is associated with poor life 
quality, decreased life expectancy and significant abnormality due to diabetes related 
complications (nephropathy, retinopathy and neuropathy) and greater risk of developing 
macro-vascular complications including peripheral vascular disease, stroke and 
ischaemic heart disease (www.who.int/diabetes). Different pathogenetic processes are 
associated with diabetes including, processes which destroy the pancreatic beta cells 
and result in insulin inferiority and those that cause resistance to insulin action. 
Abnormalities in the metabolism of proteins, carbohydrates and fats are come from 
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reduced insulin action on target organs and tissues, which is due to insensitivity or lack 
of insulin (Report of a WHO Consultation, 1999). Based on data from The International 
Diabetes Federation in 2015, 387 million people suffer from diabetes which is supposed 
to boost to 592 million by 2035. According to the statistics, 77% of diabetic patients are 
live in poor or middle income countries and in 2014, about 5 million people died from 
diabetes.  
 
1.6.1. Type 1 Diabetes 
 
Approximately 5 to 10% of all diabetic patients are diagnosed with type 1 diabetes; 
however. In type 1 diabetes, pancreatic beta-cells are destroyed which leads to diabetes 
mellitus and insulin administration is necessary to prevent the progression of 
ketoacidosis, coma and death. In order to manage type 1 diabetes several actions must 
be taken including, proper insulin administration, blood glucose monitoring, following 
healthy diet and regular screening for diabetes-related complications such as micro-
vascular and macro-vascular disease, which is a main morbidity and mortality factor of 
type 1 diabetes [109]. Family history is one of the significant risk factors for type 1 
diabetes. Moreover, any injury or diseases or infections in the pancreas can damage the 
pancreas and consequently lead to development of diabetes due to its inability to 
produce insulin [110]. 
 
1.6.2. Diabetes in Pregnancy (Gestational Diabetes) 
 
In general, during pregnancy the body becomes more resistance to insulin in order to 
provide more glucose for the fetus and therefore, pancreatic beta cells should secrete 
more insulin. Gestational diabetes is a type of diabetes which emerges in some pregnant 
women for the first time due to inability of beta cells in the pancrease to provide more 
insulin for this demand. Overweight and obese women and those women who have a 
strong family background in diabetes are at the higher risk for gestational diabetes 
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during their pregnancy. Gestational diabetes can harm the health of both the mother and 
the baby and they may develop T2DM in future [111] therefore, it is important to 
diagnose and treat it as soon as possible.  
 
1.6.3. Type 2 Diabetes 
 
Type 2 diabetes is an important progressive metabolic disease which consists of 
multiple defects including, insulin resistance, insulin secretion defects, excess glucagon 
secretion and/ or GLP-1 (Glucagon-Like Peptide-1) deficiency and possible resistance. 
Insulin resistance in liver increases basal hepatic glucose production which result in 
fasting hyperglycemia, muscle insulin resistance causes postprandial glucose disposal 
(80% of glucose uptake) in muscles. Mitochondrial dysfunction may play a role in 
muscle insulin resistance. Moreover, adipocyte insulin resistance may result in elevated 
FFA level after glucose ingestion that can cause impair insulin secretion and insulin 
resistance in liver and muscle. Insulin secretion defects can be observed due to severe 
beta-cell dysfunction in the pancreas which can become worse with insulin resistance. 
ER stress, transcription factor expression and C/EBPβ expression in beta-cells in the 
pancreas are associated with beta-cell failure [112]. Moreover, Islet amyloidosis is 
responsible for progressive loss of beta-cells [113]. Elevated plasma glucagon 
concentration is another associated factor in T2DM which contributes to increased rate 
of hepatic glucose production in T2DM patients. GLP-1 receptor agonists reduce 
plasma glucagon, enhance insulin secretion, slow gastric emptying and decrease food 
consumption by increasing satiety and therefore, GLP-1 deficiency may lead to T2DM 
[114].  
There are plenty of complications associated with T2DM which are as follows, 
cardiovascular disease, diabetic microangiopathy, diabetic neuropathy (nerve damage, 
skin ulcers, open wounds), diabetic retinopathy (blindness, macular oedema), diabetic 
nephropathy (kidney failure), diabetic ketoacidosis, diabetic gastroparesis (delayed 
gastric emptying) and diabetic ulceration (foot injury, amputation). 
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Type 2 diabetes is highly depends on our lifestyle and genetic risk factors. 85–90% of 
all diabetic patients are diagnosed with T2DM and it usually occurs in middle-aged or 
older adults who are over 45. However, younger age groups including adolescents, 
young adults and even children, increasingly develop T2DM in recent years. Most of 
the T2DM patients do not have any symptom at first stages of the disease. Early 
symptoms of T2DM are fatigue, excess thirst and urination, hunger, blurred vision and 
bladder, kidney, skin, or other inflammation or infections that takes time to heal. 
T2DM can be controlled by a combination of healthy diet, sufficient physical activity 
and weight loss. Following unhealthy diet, obesity, inadequate physical activity, aging, 
family background of diabetes and genetic factors are type 2 diabetes’ risk factors. 
As type 2 diabetes is a progressive syndrome, lifestyle changing will not be enough and 
therefore, patients will need oral anti-diabetic medications and/or insulin injections over 
time. 
 
1.6.3.1. Genetics of T2DM 
 
Several genes are associated with T2DM including, TCF7L2 (associated with decreased 
response to GLP), PPARγ (decreases insulin sensitivity and increases T2DM risk), 
CAPN10 (encodes an intracellular Ca2+-dependent cysteine protease and affects on 
insulin secretion), HNF4A (encodes hepatocyte nuclear factor 4 alpha receptor), 
adenosine receptor genes particularly, ADORA2B gene (encodes an adenosine receptor 
and is located on chromosome 17, close to the Smith-Magenis syndrome region) and 
Potassium channel genes which consist of ABCC8 and KCNJ11. ABCC8 encodes 







1.6.3.2. Diagnostic criteria for T2DM 
 
T2DM may be diagnosed through diabetes symptoms such as polyuria and polydipsia 
or/and blood glucose concentration of  200 mg/dL and higher or fasting blood glucose 
level of 126 mg/dL and higher or HbA1c test which should be equal or greater than 
6.5% to indicate diabetes. If the individuals have no diabetes symptoms, a single blood 
glucose measurement is not enough and therefore, confirmatory blood glucose 
measurement is required. 
 
1.6.3.3. Pharmacological treatment of T2DM 
 
Pharmacological products to treat T2DM are anti-hyperglycemic and they focus on 
decreasing blood glucose levels and glucose absorption in body, increase insulin 
secretion and organ sensitivity. Diabetic pharmacological agent are as follows, 
Biguanides (metformin), Insulin, Amylinomimetics, Thiazolidinediones, Sulfonylureas, 
Meglitinides, DPP-4 inhibitors, α-glucosidase inhibitors and GLP-1 receptor agonists. 
The first-line treatments for T2DM consists of metformin [118]. Moreover, exercise and 
various hypoglycemic agents can decrease oxidative stress in diabetic patients by 
improving mitochondrial function and decreasing NOX activity [119].  
Furthermore, it has been proved that some medications including ACE inhibitors , AT1-
receptor blockers and statins, improve vascular function in cardiovascular disease 





Metformin is an oral anti-hyperglycemic agent which reduces blood glucose level 
through suppressing hepatic glucose production, it also enhances insulin sensitivity and 
reduces HbA1c levels in NIDDM. However, it has some adverse reactions including, 
abdominal discomfort, stomach upset, diarrhea and lactic acidosis which can result in 
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death. The side effects may reduce by consumption of smaller divided doses. 
Prescription of metformin should be avoided for those with acute heart failure, severe 
renal function defect, liver disease and heavy alcohol ingestion and also it should not be 
used after application of iodinated contrast dyes because of the lactic acidosis risk. Use 
of metformin may induces weight loss in individuals and it does not lead to 
hypoglycemia itself but it accelerates the hypoglycemic impact of other medications 
such as insulin and sulfonylureas. Metformin can trigger AMPK phosphorylation by 
promoting AMP aggregation which consequently leads to increasing the activity of 
insulin receptor and insulin receptor substrate (IRS-2) and also enhancing translocation 
of glucose transporters. Phosphorylated AMPK inhibits the synthesis of fatty acids and 
enhances beta oxidation. Metformin possibly enhances insulin secretion and also insulin 
sensitivity by lowering free fatty acids and glucose concentrations and by preventing 




Figure 4. Metformin structure 
 
 
1.6.3.3.1.1. Lactic acidosis 
 
Lactic acidosis is a kind of metabolic acidosis and it lowers the pH of the body. It is a 
medical condition in which the lactate level, particularly L-lactate, increases in the 
body. MALA (Metformin-associated lactic acidosis) is an infrequent but fatal adverse 
effect of metformin therapy and it has up to 50% mortality. However, the metformin’s 
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independent impact on lactic acidosis development still remains unclear. As it was 
mentioned, prescription of metformin should be avoided for those with acute heart 
failure, liver disease, renal function defect and high alcohol ingestion. 
Normally, glucose is metabolized by most cells in the body to form water and carbon 
dioxid. Cells produce ATP by glycolysis in which glucose breaks down to pyruvate and 
then the pyruvate is oxidized into water and carbon dioxide through oxidative 
phosphorylation and Krebs cycle by mitochondria. The hydrolysis of ATP results in 
energy generation for the cells, hydrogen ions and Pi (inorganic phosphate). Normally, 
the mitochondria use these free hydrogen ions and Pi to produce more ATP, but during 
cellular hypoxia, ATP hydrolysis results in collection of free hydrogen ions and Pi in 
the cytosol and also the rate of glycolysis increases in the cells. Excess produced 
pyruvate is converted into lactate which causes lactic acidosis and decreases the blood 
pH. Metformin promotes anaerobic metabolism by decreasing the reducing agents 
transportation and pyruvate dehydrogenase activity in mitochondria. The anaerobic 
metabolism leads to elevated lactic acid generation due to boosted conversion of 




Insulin hormone is another treatment for both types of diabetes mellitus patients which 
treats diabetes by tight glycaemic control. As a medication, insulin can derived from 
pancreases of animals such as beef and pork or is genetically made by genetically 
modified bacteria to be able to be replaced with native human insulin. Insulin can be 
injected subcutaneously or intravenously and the dose is adjusted according to the 
patient’s weight and sensitivity to insulin. Individuals who were diagnosed with type 2 
diabetes mellitus may also need to get insulin therapy when other anti-diabetic 
medications cannot manage their blood glucose levels. There are four injectable insulin 
available for diabetic patients including, rapid acting insulin in which the effect will be 
seen in a few minutes and lasts for some hours. Short acting insulin or regular insulin in 
which the effect will be seen after couple of minutes and lasts up to 6 hours. Another 
kind is intermediate acting insulin in which the effect will be seen after about 3 hours 
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and last till 18 hours and finally, long acting insulin which has about 8 hours delay to 
start to work but the effect remains for an entire day. The most common side effect of 
insulin is hypoglycemia and its possible symptoms consists of headache, weakness, 
sweating, fast heartbeat, extreme hunger, fatigue, intense anxiety, general sense of 
confusion, tremors, irritability, rapid breathing and fainting. Moreover, other side 
effects such as enlargement of insulin injection site (hypertrophy) and rash in the body 
can be seen in insulin treated patients. Diabetic ketoacidosis (DKA) is an insulin 
complication, which can occur due to inadequate insulin administration and can lead to 
diabetic coma or death. In DKA, excessive urination in response to high glucose causes 
severe dehydration and the body doesn’t have enough insulin to use glucose. Therefore, 
the body starts to breakdown of existing protein and fat stores in order to provide 
energy, which produces ketones and release in into the blood and ketones affect the 
blood acidic and cause DKA. Symptoms of diabetic ketoacidosis are nausea, vomiting, 
and abdominal discomfort. Hyperosmolar hyperglycemic nonketotic syndrome (HHNS) 
is another insulin treatment complication which is less occur than DKA. In HHNS, 
frequent urination due to high glucose levels can cause extreme dehydration and 











Amylinomimetic is a synthetic analog of amylin, which is a neuro-hormone secreted 
simultaneously with insulin from beta cells in the pancreas and is always used with 
insulin in diabetic patients but the injections are given separately. It suppresses post-
prandial glucagon secretion, increases satiety, and slows gastric emptying without 
altering nutrient absorption. Amylinomimetic’s main adverse effects are nausea, 









Thiazolidinediones such as pioglitazone and rosiglitazone are another possible 
treatment for T2DM. They bind to the PPAR- γ receptor which regulates gene 
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expression and increase insulin sensitivity by reducing the amount of free fatty acids 
which are present in body circulation. However, TZDs can cause fluid retention, weight 














Sulfonylurea (Gliclazide) is an anti-diabetic drug which is broadly consumed in 
treatment of T2DM. It binds to sulfonylurea receptors (SUR) on pancreatic ß-cells and 
stimulates insulin secretion by closing the potassium channel which is dependent to 
ATP (KATP) which depolarize the membrane of cells and cause opening of calcium 










Another therapy option for T2DM is Megletinides which consists of nateglenide and 
rapeglenide. These drug’s binding site is close to the sulfonylureas’ binding site and 












Figure 11. Rapeglenide structure 
 
 
1.6.3.3.7. α-Glucosidase Inhibitors 
α-Glucosidase Inhibitors act in the small intestine and prevent breakdown of sucrose 
and complex carbohydrates. The common side effects are flatulence, bloating, 











Figure 13. Miglitol structure 
 
 
1.6.3.3.8. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 
 
Another class of T2DM drugs which is called dipeptidyl Peptidase-4 (DPP-4) 
Inhibitors. They partially decrease the elevated glucagon postprandially and stimulate 
insulin secretion. Urticaria and facial edema are the rare SARs of dipeptidyl Peptidase-4 
























1.6.3.3.9. GLP-1 receptor agonists 
 
GLP-1 agonists including, Liraglutide and Exenatide are another possible treatment for 
T2DM. Exenatide is the synthetic analog of exendin, and it is more resistant to DPP-4. 
They suppress postprandial glucagon secretion, stimulate insulin secretion, reduce 
postprandial glucose, increases satiety, slow gastric emptying and promotes weight loss. 
The GLP-1 agonists’ main adverse effects are nausea, vomiting, diarrhea.  
 
 










Study I: Nitrate improves mitochondrial function which makes it a potential component 
to prevent lactic acidosis that produced due to elevated lactate production in 
mitochondria. The aim of proposed study was to determine whether acute pre-treatment 
of nitrate can prevent lactic acidosis induced by a high dose of metformin. 
 
 
Study II: The aim of study II was to explore the synergistic effect of combining low 
dose of metformin and inorganic nitrate to improve metabolic functions and decrease 
blood glucose concentration in a mouse model of metabolic disease (A2BKO mice). 
  
 
3. Materials and methods 
 
3.1. Experimental animals 
 
Study I: 3-month male Wistar rats (Average 350 g of body weight) were purchased 
from Charles River Laboratory in Germany. There were 6 rats per group. 
Study II: 18 aged (Average 14 month, 45 g of body weight) A2BKO mice per each 
treatment group were used. The mice were 11 times back crossed to a C57BL/6J 
background and adenosine A2B receptor gene was deleted in them. Moreover, 6 aged 
(Average 12 month, 30 g of body weight) wild type mice from heterozygous breeding 
pairs were used in order to demonstrate the phenotype in the A2BKO mice. For all 
experiments both sexes were used. 
All the animals were housed based on standard temperature (21-22ºC), humidity and 
illumination (12 hours light/darkness). Animals were kept in their new cage 
environment at least one week before the initiation of the experiments and adequate 
amounts of food and water were provided for them in order to adjust to new 
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environment. All the experiments were authorized by the Stockholm’s Ethics 




Metformin (1, 1-Dimethylbiguanide hydrochloride) and sodium nitrate (NaNO3) was 
provided from Sigma Chemical. The lactate was detected by Cobas b 123 Sensor 
Cartridge BG/ISE/GLU/LAC (Roche Diagnostics GmbH).  
 
3.3. Experimental protocols 
 
Study I: Rats were anesthetized individually with isoflurane and we catheterized their 
femoral vein with polyethylene tubing for metformin infusion. The animals were pre-
treated with intraperitoneal injection of placebo (NaCl, 0.9%) or inorganic nitrate 
(NaNO3; 10 mg/kg body weight). Metformin infusion to femoral vein was performed 
by syringe pump. Dissolved metformin in saline was administered to the animals for 2 
h. The constant metformin infusion dose was 125 mg/h/kg and the administration rate 
was 8.0 ml/h/kg. The tail blood was sampled at 0, 30, 60, 90 and 120 minutes during the 




Figure 20. Metformin infusion into rat’s femoral vein (modified from [122]). 
 
Study II: A2BKO mice were pre-treated with acute intraperitoneal injection of placebo 
(NaCl 0.9%) or the anti-diabetic drug metformin (C4H11N5; 3.8 mg/kg body weight) or 
combination of inorganic nitrate and metformin (NaNO3; 10 mg/kg body weight, 
C4H11N5; 3.8 mg/kg body weight), 60 minutes before IP-GTT. After 1 hour 
intraperitoneal injection of D-glucose was performed (2 g/kg body weight) which was 
followed by tail blood collection at -60, 0, 15, 30, 60, and 120 min. The mice were 
fasted for 5 hours (no food but free access to water) before the initiation of the 
experiments and separated in single cages 1 hour prior the experiment. Finally, blood 








Figure 21. Intra-peritoneal glucose tolerance test (IPGTT) protocol in mice. 
 
3.4.Plasma nitrate and nitrite 
 
Plasma levels of nitrate and nitrite were determined by HPLC (ENO-20 NOx 
analyzer). The samples of plasma were centrifuged at 4°C 10000 g for 10 minutes 
after their extraction with methanol (1:2). Reversed-phase ion-pairing 
chromatography was used to separate nitrate and nitrite which was followed by 
conversion of nitrate to nitrite using reduced copper and cadmium. In order to form 





3.5. Statistical Analysis 
 
Data are revealed as means ± SEM. Unpaired or paired t-test were applied in order to 
perform single comparisons between normally distributed data and one-Way ANOVA 
coupled with Bonferroni’s post-hoc test was performed to statistically compare different 
treatments groups to the control group and to be able to do more than one comparison 
with the same variable (GraphPad Prism 6 Software). Statistical significance threshold 
was p < 0.05. 
 
4. Results and Discussion 
 
Study I: In study I, we investigated whether inorganic nitrate could prevent lactic 
acidosis caused by acute administration of metformin in rats. The two potential 
mechanisms for development of lactic acidosis, induced by metformin, are as follows: 
1) Metformin augments the lactate production in peripheral tissue [123]; and 2) 
Inhibition of mitochondrial respiration by metformin consequently can inhibit lactate 
transport, metabolism and clearance in the liver, heart and muscle. As NO directly 
affects mitochondrial respiration [41], we hypothesised that inorganic nitrate which 
consequently converts to NO, may prevent lactic acidosis by counteracting the 
mitochondrial effects of metformin. Therefore, lactic acidosis was induced by constant 
intravenous infusion of metformin at the dose of 125 mg/h/kg in rats. The blood lactate 
concentration at different time points is shown in Figure 22. The lactate concentration in 
blood started to increase significantly after 30 minutes of metformin infusion and 
continued to increase until 120 minutes after which the animals were killed. As shown 
in figure 22, there was no significant difference between the placebo pre-treatment 
group and the nitrate pre-treated group (P value 0.24).  
Therefore, we conclude from this study that pre-treatment with inorganic nitrate cannot 





Figure 22. Blood lactate concentration at different time points in Wister rats pre-treated 
with placebo (NaCl, n=6) or inorganic nitrate (NaNO3, n = 6) and then infused with 
metformin to cause lactic acid acidosis. 
 
Study II: As inorganic nitrate targets multiple aspects of the metabolic disease, the 
main aim of study II was to explore whether nitrate in combination with the anti-
diabetic drug metformin, has a synergistic effect and can decrease blood glucose levels 
more. This combination, if successful, may be beneficial to control progression of type 
2 diabetes by enabling lowering of the required dose of metformin (less risk of side 
effects) with preserved effects. 
In agreement with our previous findings, as shown in figure 23, A2BKO mice which is 
a solid animal model of metabolic syndrome with hyperglycemia, poor glucose 
clearance, obesity and hepatic inflammation, displayed impaired glucose clearance 
compared with age-matched Wild type controls [85]. In our previous study, inorganic 
nitrate was able to decrease blood glucose level by targeting NOX activity and AMPK 
activation in the liver of aged A2BKO mice [40]. It increases phosphorylation levels of 
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AMPK and decreases NOX activity which are important regulators of glucose 
homeostasis and clearance in the liver [99, 100]. 
According to figure 24, intraperitoneal administration of a low dose of metformin was 
associated with improved glucose clearance at 30 min in A2BKO mice compared to 
control group with the P value of <0.05, whereas the overall glucose clearance (Total 
area under the curve) was not significantly affected (p=0.06) 
Combination of metformin and inorganic nitrate was associated with improved glucose 
clearance at 15, 30 and 60 minutes after injection of glucose in A2BKO mice compared 
to the control group.  
Comparing the low dose of metformin with the combination of nitrate and metformin, it 
was noted that in the combination group glucose disposal was numerically better at 15, 
30 and 60 minutes after injection of glucose, and the total AUC trended to be reduced. 
The reason for the lack of a clear synergistic effect can only be speculated upon but may 
be due to the fact that the tested compounds act through the same mechanism in 
targeting NOX activity and AMPK phosphorylation. Moreover, a glucose tolerance test 
is not always the most affected parameter in metformin treatment particularly at low 
doses and therefore other parameters such as insulin tolerance test, NOX and AMPK 





Figure 23. Intraperitoneal glucose tolerance test (IPGTT) in wildtype (WT, n=6) and 
adenosine A2B receptor knockout mice (A2BKO, n=18), and effects of acute treatment 




Figure 24. The effect of combination of metformin and inorganic nitrate on plasma 
glucose levels in A2BKO mice after placebo (NaCl, n=18), metformin (MET, n=18) or 
combination of metformin and inorganic nitrate injection (MET + NO3, n=18). 
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Nitrate and nitrite in plasma 
As expected, both plasma nitrate (Figure 25) and nitrite (Figure 26) levels in A2B −/− 
mice which were pre-treated by combination of metformin and nitrate increased 
significantly in comparison with saline and metformin pre-treated mice. (p < 0.05) 
 
 
Figure 25. Nitrate levels in plasma samples of different pre-treated groups of A2BKO 
mice (n = 6/group).   
 
 
Figure 26. Nitrite levels in plasma samples of different pre-treated groups of A2BKO 





I would like to illustrate my gratitude to my Supervisor Prof. Jon Lundberg, who provided me 
an opportunity to join his research group, for his continuous support and motivation. 
My sincere thanks also goes to Prof. Mattias Carlström for his support and valuable guidance 
during this project. 
Moreover, I would like to thank Marcelo Montenegro, Margaretha Stensdotter-Larsson, 
Carina Nihlén, Maria Peleli, Isabel Cordero, Christa Zollbrecht and Annika Olsson. 
Without their help and support it would not be possible to perform this research. 


























1. Kylin E. Studies of the hypertension–hyperglycemia hyperuricemia syndrome (Studien 
ueber das hypertonie-hypergly-ka¨miehyperurika¨miesyndrom. Zentral-blatt fuer Innere 
Medizin 1923; 44: 105–27. 
2. Vague J. Sexual differentiation. A factor affecting the forms of obesity. Press 
Med 1947; 30: 339–40. 
3. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. 
Diabetes 1988; 37: 1595–607. 
4. Lam D.W, LeRoith D. Metabolic Syndrome. Endotext. Inc.; 2000-2015 May 19. 
5. Wannamethee S, Shaper A, Lennon L. Metabolic syndrome vs Framingham 
Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes 
mellitus. Arch Intern Med 2005; 165(22):2644-50. 
6. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 
38(1):64-80. 
7. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev 2007; 
29:1-5. 
8. Grundy S. Obesity, metabolic syndrome, and cardiovascular disease. J Clin 
Endocrinol Metab 2004; 89(6):2595-600. 
9. Flegal K, Carroll M, Ogden C. Prevalence and trends in obesity among US 
adults, 1999-2000. JAMA 2002; 288(14):1723-7. 
10. Park Y, Zhu S, Palaniappan L. The metabolic syndrome: prevalence and 
associated risk factor findings in the US population from the Third National 
Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 
163(4):427-36. 
11. Blake R, Trounce I.A. Mitochondrial dysfunction and complications associated 
with diabetes. Biochim. Biophys.Acta. 2014, 1840, 1404-1412. 
12. Willett W, Manson J, Stampfer M. Weight, weight change, and coronary heart 




13. Alley D, Chang V. Metabolic syndrome and weight gain in adulthood. J 
Gerontol A Biol Sci Med Sci 2010; 65(1):111-7. 
14. Thompson P, Buchner D, Pina I. Exercise and physical activity in the prevention 
and treatment of atherosclerotic cardiovascular disease: a statement from the 
Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and 
Prevention) and the Council on Nutrition, Physical Activity, and Metabolism 
(Subcommittee on Physical Activity). Circulation 2003; 107(24):3109-16. 
15. Rennie K, McCarthy N, Yazdgerdi S. Association of the metabolic syndrome 
with both vigorous and moderate physical activity. Int J Epidemiol. 2003; 
32(4):600-6. 
16. Ford E, Kohl H.R, Mokdad A. Sedentary behavior, physical activity, and the 
metabolic syndrome among U.S. adults. Obes Res 2005; 13(3):608-14. 
17. Laaksonen D, Lakka H, Salonen J. Low levels of leisure-time physical activity 
and cardiorespiratory fitness predict development of the metabolic syndrome. 
Diabetes Care 2002; 25(9):1612-8. 
18. Lakka T, Laaksonen D, Lakka H. Sedentary lifestyle, poor cardiorespiratory 
fitness, and the metabolic syndrome. Med Sci Sports Exerc 2003; 35(8):1279-
86. 
19. Carroll S.H, Cooke C, Butterly R. Metabolic clustering, physical activity and 
fitness in nonsmoking, middle-aged men. Med Sci Sports Exerc 2000; 
32(12):2079-86. 
20. Katzmarzyk P, Leon A, Wilmore J. Targeting the metabolic syndrome with 
exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exerc 
2003; 35(10):1703-9. 
21. Rice B, Janssen I, Hudson R. Effects of aerobic or resistance exercise and/or diet 
on glucose tolerance and plasma insulin levels in obese men. Diabetes Care 
1999; 22(5):684-91.  
22. Hord N.G, Tang Y, Bryan N.S. Food sources of nitrates and nitrites: the 




23. Lundberg J.O, Weitzberg E, Gladwin M.T. The nitrate-nitrite-nitric oxide 
pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 2008; 7, 156–
167. 
24. Lundberg J.O, Carlström M, Larsen F.J, Weitzberg E. Roles of dietary inorganic 
nitrate in cardiovascular health and disease. Cardiovasc 2011; Res.89, 525 532.  
25. Bryan N. S, Alexander D. D, Coughlin J. R, Milkowski A.L. Ingested nitrate 
and nitrite and stomach cancer risk: an updated review. Food Chem. Toxicol. 
2012, 50, 3646–3665. 
26. Jakszyn P, Bingham S, Pera G, Agudo A. Endogenous versus exogenous 
exposure to N-nitroso compounds and gastric cancer risk in the European 
Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. 
Carcinogenesis 2006, 27, 1497–1501. 
27. Jakszyn P, Gonzalez C.A. Nitrosamine and related food intake and gastric and 
oesophageal cancer risk: a systematic review of the epidemiological evidence. 
World J. Gastroenterol. 2006, 12, 4296–4303. 
28. Cross A. J, Freedman N.D, Ren J, Ward M.H. Meat consumption and risk of 
esophageal and gastric cancer in a large prospective study. Am. J. Gastroenterol. 
2011, 106, 432–442. 
29. Van Faassen E.E, Bahrami S, Feelisch M, Hogg N, Kelm M, Kim-Shapiro D.B, 
Kozlov A.V, Li H, Lundberg J.O, Mason R, Nohl H, Rassaf T, Samouilov A, 
Slama-Schwok A, Shiva S, Vanin A.F, Weitzberg E, Zweier J, Gladwin M.T. 
Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res 
Rev, 2009. 29(5): p. 683-741. 
30. Benjamin N, O'Driscoll F, Dougall H, Duncan C, Smith L, Golden M, 
McKenzie H. Stomach NO synthesis. Nature, 1994. 368(6471): p. 502. 
31. Lundberg, J.O, Weitzberg E, Lundberg J.M, Alving K. Intragastric nitric oxide 
production in humans: measurements in expelled air. Gut, 1994. 35(11): p. 
1543-6. 
32. Duncan C, Dougall H, Johnston P, Green S, Brogan R, Leifert C, Smith L, 
Golden M, Benjamin N. Chemical generation of nitric oxide in the mouth from 
the enterosalivary circulation of dietary nitrate. Nat Med, 1995. 1(6): p. 546-51. 
48 
 
33. Lundberg, J.O, Weitzberg E, Cole J.A, Benjamin N. Nitrate, bacteria and human 
health. Nat Rev Microbiol, 2004. 2(7): p. 593-602. 
34. Lundberg, J.O, Gladwin M.T, Weitzberg E. Strategies to increase nitric oxide 
signalling in cardiovascular disease. Nat Rev Drug Discov, 2015. 14(9): p. 623-
41. 
35. Jones A.M, Vanhatalo A, Bailey S.J. Influence of dietary nitrate 
supplementation on exercise tolerance and performance. Nestle Nutr Inst 
Workshop Ser, 2013. 75: p. 27-40. 
36. Gee L.C, Ahluwalia A. Dietary Nitrate Lowers Blood Pressure: 
Epidemiological, Pre-clinical Experimental and Clinical Trial Evidence. Curr 
Hypertens Rep, 2016. 18(2): p. 17. 
37. Jansson E.A, Huang L, Malkey R, Govoni M, Nihlén C, Olsson A, Stensdotter 
M, Petersson J, Holm L, Weitzberg E, Lundberg J.O. A mammalian functional 
nitrate reductase that regulates nitrite and nitric oxide homeostasis. Nat Chem 
Biol, 2008. 4(7): p. 411-7. 
38. Peinado J.R, Diaz-Ruiz A, Frühbeck G, Malagon M.M. Mitochondria in 
metabolic disease: getting clues from proteomic studies. Proteomics. 2014 
Mar;14(4-5):452-66. 
39. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, 
Valerio A, Francolini M, Moncada S, Carruba M.O. Mitochondrial biogenesis in 
mammals: the role of endogenous nitric oxide. Science. 2003 Feb 
7;299(5608):896-9. 
40. Peleli M, Hezel M, Zollbrecht C, Persson A, Lundberg J.O, Weitzberg E, 
Fredholm B, Carlström M. In adenosine A2B knockouts acute treatment within 
organic nitrate improves glucose disposal, oxidative stress and AMPK signaling 
in the liver. Physiol. 6:222.  
41. Litvinova L, Atochin D.N, Fattakhov N, Vasilenko M, Zatolokin P, Kirienkova 
E. Nitric oxide and mitochondria in metabolic syndrome. Front Physiol. 2015 
Feb 17;6:20. 
42. Kashyap S.R, Roman L.J, Lamont J, Masters B.S, Bajaj M, Suraamornkul S, 
Belfort R, Berria R, Kellogg D.L Jr, Liu Y, DeFronzo R.A. Insulin resistance is 
49 
 
associated with impaired nitric oxide synthase activity in skeletal muscle of type 
2 diabetic subjects. J Clin Endocrinol Metab. 2005 Feb;90(2):1100-5. 
43. Shankar R.R, Wu Y, Shen H.Q, Zhu J.S, Baron A.D. Mice with gene disruption 
of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. 
Diabetes. 2000 May;49(5):684-7. 
44. Alvarado-Vásquez N, Zapata E, Alcázar-Leyva S, Massó F, Montaño L.F. 
Reduced NO synthesis and eNOS mRNA expression in endothelial cells from 
newborns with a strong family history of type 2 diabetes. Diabetes Metab Res 
Rev. 2007 Oct;23(7):559-66. 
45. Lundberg J.O, Gladwin M.T, Ahluwalia A, Benjamin N, Bryan N.S ,Butler A. 
Nitrate and nitrite in biology, nutrition and therapeutics. Nat. Chem. Biol 2009; 
5,865 869. 
46. Carlström M, Larsen F.J, Nyström T, Hezel M, Borniquel S, Weitzberg E. 
Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial 
nitric oxide synthase deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2010; 
107,17716 17720.  
47. Singamsetty S, Watanabe Y, Guo L, Corey C, Wang Y, Tejero J. Inorganic 
nitrite improves components of the metabolic syndrome independent of weight 
change in a murine model of obesity and insulin resistance. J. Physiol. 2015; 
593(14):3135-45. 
48. Carlström, M., C.S. Wilcox, and W.J. Welch, Adenosine A2A receptor 
activation attenuates tubuloglomerular feedback responses by stimulation of 
endothelial nitric oxide synthase. Am J Physiol Renal Physiol, 2011. 300(2): p. 
F457-64. 
49. Gao X, Yang T, Liu M, Peleli M. NADPH oxidase in the renal microvasculature 
is a primary target for blood pressure-lowering effects by inorganic nitrate and 
nitrite. Hypertension 2014, 65, 161–170. 
50. Duncan R.E, Ahmadian M, Jaworski K, Sarkadi-Nagy E. Regulation of lipolysis 
in adipocytes. Annu. Rev. Nutr. 2007, 27, 79–101. 
51. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological 
significance. Physiol. Rev. 2004, 84, 277– 359. 
50 
 
52. Kopecky J, Clarke G, Enerb ack S, Spiegelman B. Expression of the 
mitochondrial uncoupling protein gene from the aP2 gene promoter prevents 
genetic obesity. J. Clin. Invest. 1995, 96, 2914–2923. 
53. Roberts L.D, Ashmore T, Kotwica A.O, Murfitt S.A. Inorganic nitrate promotes 
the browning of white adipose tissue through the nitrate-nitrite-nitric oxide 
pathway. Diabetes 2014, 64, 471–484. 
54. Kapil V, Milsom A.B, Okorie M, Maleki-Toyserkani S. Inorganic nitrate 
supplementation lowers blood pressure in humans: role for nitrite-derived NO. 
Hypertension 2010, 56, 274–281. 
55. Bryan N.S, Fernandez B.O, Bauer S.M, Garcia-Saura M.F. Nitrite is a signaling 
molecule and regulator of gene expression in mammalian tissues. Nat. Chem. 
Biol. 2005, 1, 290–297. 
56. Katafuchi T, Garbers D.L, Albanesi J.P. CNP/GC-B system: a new regulator of 
adipogenesis. Peptides 2010, 31, 1906–1911. 
57. Nishikimi T, Iemura-Inaba C, Akimoto K, Ishikawa K. Stimulatory and 
Inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPR-C/G(i) 
pathways in rat cultured adipocytes. Regul. Pept. 2009, 153, 56–63. 
58. Zhang X, Ji J, Yan G, Wu J. Sildenafil promotes adipogenesis through a PKG 
pathway. Biochem. Biophys. Res. Commun. 2010, 396, 1054–1059. 
59. Mitschke M.M, Hoffmann L.S, Gnad T, Scholz D, Kruithoff K, Mayer P, Haas 
B, Sassmann A, Pfeifer A, Kilic A. Increased cGMP promotes healthy 
expansion and browning of white adipose tissue. FASEB J. 2013 
Apr;27(4):1621-30. 
60. McNally B, Griffin J.L, Roberts L.D. Dietary inorganic nitrate: From villain to 
hero in metabolic disease?. Mol Nutr Food Res. 2016 Jan;60(1):67-78. 
61. Sowers J.R, Epstein M, Frohlich E.D. Diabetes, hypertension and cardiovascular 
disease: an update. Hypertension 2001, 37, 1053–1059. 
62. Wang W, Lee E.T, Fabsitz R.R, Devereux R.A longitudinal study of 
hypertension risk factors and their relation to cardiovascular disease: the Strong 
Heart Study. Hypertension 2006, 47, 403–409. 
51 
 
63. Puddu P, Puddu G.M, Zaca F, Muscari A. Endothelial dysfunction in 
hypertension. Acta Cardiol. 2000, 55, 221– 232. 
64. Cai H, Harrison D.G. Endothelial dysfunction in cardiovascular diseases: The 
role of oxidant stress. Circ. Res. 2000, 87, 840–844. 
65. Cannon R.O. Role of nitric oxide in cardiovascular disease: focus on the 
endothelium. Clin. Chem. 1998, 44, 1809–1819. 
66. Hobbs D.A, George T.W, Lovegrove J.A. The effects of dietary nitrate on blood 
pressure and endothelial function: a review of human intervention studies. Nutr. 
Res. Rev. 2013, 26, 210–222. 
67. Larsen F.J, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E. Effects of dietary 
nitrate on blood pressure in healthy volunteers. N Engl J Med. 2006 Dec 
28;355(26):2792-3. 
68. Kenjale A.A, Ham K.L, Stabler T, Robbins J.L. Dietary nitrate supplementation 
enhances exercise performance in peripheral arterial disease. J. Appl. Physiol. 
2011, 110, 1582–1591. 
69. Kapil V, Khambata R.S, Robertson A, Caulfield M.J. Dietary nitrate provides 
sustained blood pressure lowering in hypertensive patients: a randomized, phase 
2, double-blind, placebo-controlled study. Hypertension 2015, 65, 320–327. 
70. Patzak A, Persson A.E.G. Angiotensin II-nitric oxide interaction in the kidney. 
Curr. Opin. Nephrol. Hypertens. 2007, 16, 46–51. 
71. Ashmore T, Fernandez B.O, Evans C.E, Huang Y. Suppression of erythropoiesis 
by dietary nitrate. FASEB J. 2014, 29, 1102–1112. 
72. Jae S.Y, Kurl S, Laukkanen J.A, Heffernan K.S. Higher blood hematocrit 
predicts hypertension in men. J. Hypertens. 2014, 32, 245–250. 
73. Liu X, Liang J, Qiu Q, Zhu Y. Association of hematocrit and pre-hypertension 
among Chinese adults: the CRC Study. Cell Biochem. Biophys. 2015, 71, 1123–
1128. 
74. Holloway C.J, Montgomery H.E, Murray A.J, Cochlin L.E. Cardiac response to 
hypobaric hypoxia: persistent changes in cardiac mass, function, and energy 
metabolism after a trek to Mt. Everest base camp. FASEB J. 2011, 792–796. 
52 
 
75. Heather L.C, Cole M.A, Tan J.J, Ambrose L.J.A. Metabolic adaptation to 
chronic hypoxia in cardiac mitochondria. Basic Res. Cardiol. 2012, 107, 268–
280. 
76. Ashmore T, Fernandez B. O, Branco-Price C, West J. A. Dietary nitrate 
increases arginine availability and protects mitochondrial complex I and 
energetics in the hypoxic rat heart. J. Physiol. 2014, 592, 4715–4731. 
77. Pernow J, Jung C. Arginase as a potential target in the treatment of 
cardiovascular disease: reversal of arginine steal? Cardiovasc. Res. 2013, 98, 
334–343. 
78. Willam C, Maxwell P. H, Nichols L, Lygate C. HIF prolyl hydroxylases in the 
rat; organ distribution and changes in expression following hypoxia and 
coronary artery ligation. J. Mol. Cell. Cardiol. 2006, 41, 68–77. 
79. Murray A.J, Lygate C.A, Cole M.A, Carr C.A. Insulin resistance, abnormal 
energy metabolism and increased ischemic damage in the chronically infarcted 
rat heart. Cardiovasc. Res. 2006, 71, 149–157. 
80. Murray A.J, Cole M.A, Lygate C.A, Carr C.A. Increased mitochondrial 
uncoupling proteins, respiratory uncoupling and decreased efficiency in the 
chronically infarcted rat heart. J. Mol. Cell. Cardiol. 2008, 44, 694–700. 
81. Dupuis J. Nitrates in congestive heart failure. Cardiovasc Drugs Ther. 1994 
Jun;8(3):501-7. 
82. Ahluwalia A, Gladwin M, Coleman G.D, Hord N, Howard G, Kim‐Shapiro D.B, 
Lajous M, MD, Larsen F.J, Lefer D.J, McClure L.A, Nolan B.T, Pluta R, 
Schechter A, Wang C.Y, Ward M.H, Harman J.L. Dietary Nitrate and the 
Epidemiology of Cardiovascular Disease: Report From a National Heart, Lung, 
and Blood Institute Workshop. J Am Heart Assoc. 2016 Jul; 5(7): e003402. 
83. Fredholm B.B, IJzerman A, Jacobson K, Klotz K, Linden J. International Union 
of Pharmacology. Nomenclature and classification of adenosine receptors. 
Pharmacol. Rev. 2001; 53:527–552.  
84. Fredholm B.B, IJzerman A, Jacobson K, Linden J, Müller C. International 
Union of Basic and Clinical Pharmacology. Nomenclature and classification of 
adenosine receptors — an update. Pharmacol. Rev. 2011; 63:1–34. 
53 
 
85. Johnston-Cox H, Koupenova M, Yang D, Corkey B, Gokce N, Farb M, 
LeBrasseur N, Ravid K. The A2b adenosine receptor modulates glucose 
homeostasis and obesity. PLoS One, 2012. 7(7): p. e40584. 
86. Takedachi M, Oohara H, Smith B, Iyama M, Kobashi M, Maeda K, Long CL, 
Humphrey M, Stoecker B, Toyosawa S, Thompson L, Murakami S. CD73-
generated adenosine promotes osteoblast differentiation. J. Cell. Physiol. 2012; 
227:2622–2631.  
87. Carroll S.H, Wigner N.A, Kulkarni N, Johnston-Cox H, Gerstenfeld L.C, Ravid 
K. A2B adenosine receptor promotes mesenchymal stem cell differentiation to 
osteoblasts and bone formation in vivo. J. Biol. Chem. 2012; 287:15718–15727.  
88. Csoka, B, Koscsó B, Töro G, Kókai E,  Virág E, Németh Z, Pacher P, Bai P, 
Haskó G. A2B adenosine receptors prevent insulin resistance by inhibiting 
adipose tissue inflammation via maintaining alternative macrophage activation. 
Diabetes, 2014. 63(3): p. 850-66. 
89. Rui L., Energy metabolism in the liver. Compr Physiol, 2014. 4(1): p. 177-97. 
90. Vozarova B, Stefan N, Lindsay R, Saremi A, Pratley R, Bogardus C, Tataranni 
A. High alanine aminotransferase is associated with decreased hepatic insulin 
sensitivity and predicts the development of type 2 diabetes. Diabetes, 2002. 
51(6): p. 1889-95. 
91. Banskota S, Regmi S.C, Kim JA. NOX1 to NOX2 switch deactivates AMPK 
and induces invasive phenotype in colon cancer cells through overexpression of 
MMP-7. Mol Cancer, 2015. 14: p. 123. 
92. Guichard C, Moreau R, Pessayre D, Epperson T.K, Krause K.H. NOX family 
NADPH oxidases in liver and in pancreatic islets: a role in the metabolic 
syndrome and diabetes? Biochem Soc Trans, 2008. 36(Pt 5): p. 920-9. 
93. Koupenova M, Johnston H, Vezeridis A, Gavras H, Yang D, Zannis V,  Ravid 
K. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. 
Circulation, 2012. 125(2): p. 354-63. 
94. Johnston-Cox H, Koupenova M, Yang D, Corkey B, Gokce N, Farb M.G, 
LeBrasseur N, Ravid K. The A2b adenosine receptor modulates glucose 
homeostasis and obesity. PLoS One. 2012;7(7):e40584. 
54 
 
95. Ansari H.R, Nadeem A, Talukder H, Sakhalkar S, Mustafa J.M. Evidence for 
the involvement of nitric oxide in A2B receptor-mediated vasorelaxation of 
mouse aorta. Am J Physiol Heart Circ Physiol, 2007. 292(1): p. H719-25. 
96. Yang D, Zhang Y, Nguyen H.G, Koupenova M, Chauhan A.K, Makitalo M, 
Jones M.R, St Hilaire C, Seldin D.C, Toselli P, Lamperti E, Schreiber B.M, 
Gavras H, Wagner D.D, Ravid K. The A2B adenosine receptor protects against 
inflammation and excessive vascular adhesion. J. Clin. Invest. 2006; 116:1913–
1923.  
97. Eckle T, Faigle M, Grenz A, Laucher S, Thompson L.F, Eltzschig H.K. A2B 
adenosine receptor dampens hypoxia-induced vascular leak. Blood. 2008; 
111:2024–2035. 
98. Schulte G, Fredholm BB. Human adenosine A1, A2A, A2B, and A3 receptors 
expressed in Chinese hamster ovary cells all mediate the phosphorylation of 
extracellular-regulated kinase 1/2. Mol. Pharmacol. 2000; 58:477–482. 
99. Viana, A.Y, Sakoda H, Anai M, Fujishiro M, Ono H, Kushiyama A, Fukushima 
Y, Sato Y, Oshida Y, Uchijima Y, Kurihara H, Asano T. Role of hepatic AMPK 
activation in glucose metabolism and dexamethasone-induced regulation of 
AMPK expression. Diabetes Res Clin Pract, 2006. 73(2): p. 135-42. 
100. Wang S, P. Song, M.H. Zou. AMP-activated protein kinase, stress 
responses and cardiovascular diseases. Clin Sci (Lond), 2012. 122(12): p. 555-
73. 
101. Kamga Pride C, Mo L, Quesnelle K, Dagda R.K, Murillo D, Geary L, 
Corey C, Portella R, Zharikov S, St Croix C, Maniar S, Chu C.T, Khoo N.K, 
Shiva S. Nitrite activates protein kinase A in normoxia to mediate mitochondrial 
fusion and tolerance to ischaemia/reperfusion. Cardiovasc Res, 2014. 101(1): p. 
57-68. 
102. Lai YC, Tabima D.M, Dube J.J, Hughan K.S, Vanderpool R.R, 
Goncharov D.A, St Croix C.M, Garcia-Ocaña A, Goncharova E.A, Tofovic S.P, 
Mora A.L, Gladwin M.T. SIRT3-AMP-Activated Protein Kinase Activation by 
Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary 
Hypertension Associated With Heart Failure With Preserved Ejection Fraction. 
Circulation, 2016. 133(8): p. 717-31. 
55 
 
103. Kraegen E.W, Saha A.K, Preston E, Wilks D, Hoy A.J, Cooney G.J, 
Ruderman N.B. Increased malonyl-CoA and diacylglycerol content and reduced 
AMPK activity accompany insulin resistance induced by glucose infusion in 
muscle and liver of rats. Am J Physiol Endocrinol Metab, 2006. 290(3): p. 
E471-9. 
104. Towler M.C, Hardie D.G. AMP-activated protein kinase in metabolic 
control and insulin signaling. Circ Res, 2007. 100(3): p. 328-41. 
105. Adachi M, Brenner D.A. High molecular weight adiponectin inhibits 
proliferation of hepatic stellate cells via activation of adenosine 
monophosphateactivated protein kinase. Hepatology, 2008. 47(2): p. 677-85. 
106. Piwkowska A, Rogacka D, Jankowski M, Dominiczak M.H, Stepiński 
J.K, Angielski S.  Metformin induces suppression of NAD(P)H oxidase activity 
in podocytes. Biochem Biophys Res Commun, 2010. 393(2): p. 268-73.  
107. Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, Pagnin E, 
Fadini G.P, Albiero M, Semplicini A, Avogaro A. Rosiglitazone reduces 
glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-
dependent mechanism. Arterioscler Thromb Vasc Biol, 2007. 27(12): p. 2627-
33.  
108. Balteau M, Van Steenbergen A, Timmermans A.D, Dessy C, Behets-
Wydemans G, Tajeddine N, Castanares-Zapatero D, Gilon P, Vanoverschelde 
J.L, Horman S, Hue L, Bertrand L, Beauloye C. AMPK activation by glucagon-
like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in 
adult cardiomyocytes. Am J Physiol Heart Circ Physiol, 2014. 307(8): p. 
H1120-33. 
109. Daneman D. Type 1 diabetes. The Lancet, Toronto: 2006;36, 
(9513):847-858. 
110. Janeway C.A Jr, Travers P, Walport M. Autoimmune responses are 
directed against self antigens. Immunobiology: The Immune System in Health 
and Disease. 5th edition. Garland Science; 2001. 
111. Harris M.I. Epidemiologic correlated of NIDDM in Hispanics, whites 
and blacks in the US population. Diabetes Care 1991;14(suppl3):639-648. 
56 
 
112. Matsuda T, Kido Y, Asahara S, Kaisho T, Tanaka T, Hashimoto N, 
Shigeyama Y, Takeda A, Inoue T, Shibutani Y, Koyanagi M, Hosooka T, 
Matsumoto M, Inoue H, Uchida T, Koike M, Uchiyama Y, Akira S, Kasuga M. 
Ablation of C/EBPbeta alleviates ER stress and pancreatic beta cell failure 
through the GRP78 chaperone in mice. J Clin Invest. 2010 Jan;120(1):115-26.  
113. Marzban L, Park K, Verchere C.B. Islet amyloid polypeptide and type 2 
diabetes. Exp Gerontol. 2003 Apr;38(4):347-51. 
114. Nauck M.A, Vardarli I, Deacon C.F, Holst J.J, Meier J.J. Secretion of 
glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. 
Diabetologia. 2011 Jan;54(1):10-8. 
115. Jay M.A, Ren J. Peroxisome proliferator-activated receptor (PPAR) in 
metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev. 2007 
Feb;3(1):33-9. 
116. Cauchi S, Froguel P. TCF7L2 genetic defect and type 2 diabetes. Curr 
Diab Rep. 2008 Apr;8(2):149-55. 
117. Odgerel Z, Lee H.S, Erdenebileg N, Gandbold S, Luvsanjamba M, 
Sambuughin N, Sonomtseren S, Sharavdorj P, Jodov E, Altaisaikhan K, 
Goldfarb L.G. Genetic variants in potassium channels are associated with type 2 
diabetes in a Mongolian population. J Diabetes. 2012 Sep; 4 (3):238-42. 
118. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of 
hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to 
a position statement of the American Diabetes Association and the European 
Association for the Study of Diabetes. Diabetologia 2015;58:429-42. 
119. Shen GX. Oxidative stress and diabetic cardiovascular disorders: roles of 
mitochondria and NADPH oxidase. Can J Physiol Pharmacol. 2010 
Mar;88(3):241-8. 
120. Münzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic 
target in cardiovascular disease? Eur Heart J. 2010 Nov;31(22):2741-8. 
121. Buysschaert M, Dramaix A.S, Wallemacq P, Hermans M.: 
Hyperhomocysteinemia in type 2 diabetes: Relationship to macro angiopathy, 
nephropathy and insulin resistance. Diabetes care 2000; 23: 1816-1822. 
57 
 
122. Ciulla M.M, Perrucci G.L, Magrini F. Adaptation and Evolution in a 
Gravitational Environment — A Theoretical Framework for the Limited Re–
Generative Post–Natal Time Window of the Heart in Higher Vertebrates. 
Regenerative Medicine and Tissue Engineering book, 2013, under CC BY 3.0 
license. 
123. Borst S.E, Snellen H.G. Metformin, but not exercise training, increases 
insulin responsiveness in skeletal muscle of Sprague-Dawley rats. Life Sci. 2001 
Aug 17;69(13):1497-507. 
 
 
 
